Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, ...

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the ...

Gilead Sciences on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year financial ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2025 results , with sales up 1.8% year on year to $7.08 ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.96 billion. On a per-share basis, the Foster City, ...

Mid Cap Growth fund seekers should not consider taking a look at Eventide Gilead Fund N (ETGLX) at this time. ETGLX possesses a Zacks Mutual Fund Rank of 5 (Strong Sell), which is based on various ...